Combination Therapies With Adagrasib In Patients With Advanced NSCLC With KRAS G12C Mutation

Overview

About this study

The purpoes of this study is to evaluate the clinical effectiveness of combination therapies with adagrasib in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with TPS ≥ 1% and KRAS G12C mutation

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Histologically confirmed diagnosis of unresectable or metastatic NSCLC (squamous or
nonsquamous) with KRAS G12C mutation and PD-L1 TPS ≥ 1%

Exclusion Criteria:

- Prior systemic treatment for locally advanced or metastatic NSCLC, including
chemotherapy, immune checkpoint inhibitor therapy (CIT), or any therapy targeting KRAS
G12C mutation (eg, sotorasib)

- Radiation to the lung ≥ 30 Gy within 6 months prior to first dose of study treatment

- Active brain metastases

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/9/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Yanyan Lou, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Konstantinos Leventakos, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions